Published in Cancer Microenviron on March 05, 2010
The human gut microbiome as a screening tool for colorectal cancer. Cancer Prev Res (Phila) (2014) 2.08
Loss of Stromal IMP1 Promotes a Tumorigenic Microenvironment in the Colon. Mol Cancer Res (2015) 1.44
Aberrant septin 9 DNA methylation in colorectal cancer is restricted to a single CpG island. BMC Cancer (2013) 0.97
Peptides as targeting probes against tumor vasculature for diagnosis and drug delivery. J Transl Med (2012) 0.96
Mechanistic aspects of COX-2 expression in colorectal neoplasia. Recent Results Cancer Res (2013) 0.95
RUNX1 is essential for mesenchymal stem cell proliferation and myofibroblast differentiation. Proc Natl Acad Sci U S A (2014) 0.95
Prognostic value of innate and adaptive immunity in colorectal cancer. World J Gastroenterol (2013) 0.90
Urokinase-type plasminogen activator receptor (uPAR) on tumor-associated macrophages is a marker of poor prognosis in colorectal cancer. Cancer Med (2014) 0.89
Macrophages associated with tumors as potential targets and therapeutic intermediates. Nanomedicine (Lond) (2014) 0.89
Cancer-associated fibroblasts connect metastasis-promoting communication in colorectal cancer. Front Oncol (2015) 0.87
Natural history of hepatic metastases from colorectal cancer--pathobiological pathways with clinical significance. World J Gastroenterol (2014) 0.86
Cytokine-Induced Modulation of Colorectal Cancer. Front Oncol (2016) 0.84
Hypoxia triggers a Nur77-β-catenin feed-forward loop to promote the invasive growth of colon cancer cells. Br J Cancer (2014) 0.84
Phytochemicals and colorectal cancer prevention--myth or reality? Nat Rev Gastroenterol Hepatol (2011) 0.84
Autophagy proteins regulate cell engulfment mechanisms that participate in cancer. Semin Cancer Biol (2013) 0.83
Postoperative simple biochemical markers for prediction of bone metastases in Egyptian breast cancer patients. Ecancermedicalscience (2013) 0.81
Strawberry phytochemicals inhibit azoxymethane/dextran sodium sulfate-induced colorectal carcinogenesis in Crj: CD-1 mice. Nutrients (2015) 0.80
The oncomodulatory role of human cytomegalovirus in colorectal cancer: implications for clinical trials. Front Oncol (2014) 0.80
PPARδ and PGE2 signaling pathways communicate and connect inflammation to colorectal cancer. Inflamm Cell Signal (2014) 0.79
The role of Snail1 transcription factor in colorectal cancer progression and metastasis. Contemp Oncol (Pozn) (2015) 0.78
Transporter function and cyclic AMP turnover in normal colonic mucosa from patients with and without colorectal neoplasia. BMC Gastroenterol (2012) 0.78
Tumor microsomal metabolism of the food toxicant, benzo(a)pyrene, in ApcMin mouse model of colon cancer. Tumour Biol (2012) 0.78
Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response? Oncotarget (2016) 0.76
Role of stromal-epithelial interaction in the formation and development of cancer cells. Cancer Microenviron (2013) 0.76
Mimicking Metastases Including Tumor Stroma: A New Technique to Generate a Three-Dimensional Colorectal Cancer Model Based on a Biological Decellularized Intestinal Scaffold. Tissue Eng Part C Methods (2016) 0.76
Changes in cellular mechanical properties during onset or progression of colorectal cancer. World J Gastroenterol (2016) 0.76
Mechanistic roles of epithelial and immune cell signaling during the development of colitis-associated cancer. Cancer Res Front (2016) 0.76
Detection of extracellular matrix modification in cancer models with inverse spectroscopic optical coherence tomography. Phys Med Biol (2016) 0.76
The Promoting Effect of the Extracellular Matrix Peptide TNIIIA2 Derived from Tenascin-C in Colon Cancer Cell Infiltration. Int J Mol Sci (2017) 0.75
Myeloid-derived suppressor cells and associated events in urethane-induced lung cancer. Clinics (Sao Paulo) (2013) 0.75
Opioids, Neutral Endopeptidase, its Inhibitors and Cancer: Is There a Relationship among them? Arch Immunol Ther Exp (Warsz) (2014) 0.75
Tumor budding as a potential histopathological biomarker in colorectal cancer: hype or hope? World J Gastroenterol (2012) 0.75
Identification of a characteristic vascular belt zone in human colorectal cancer. PLoS One (2017) 0.75
On the prognostic & predictive impact of immune cells system in colorectal cancer. Indian J Med Res (2012) 0.75
G protein-coupled receptor GPR55 promotes colorectal cancer and has opposing effects to cannabinoid receptor 1. Int J Cancer (2017) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Multilineage potential of adult human mesenchymal stem cells. Science (1999) 66.19
Dendritic cells and the control of immunity. Nature (1998) 56.54
Inflammation and cancer. Nature (2002) 53.78
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
Cancer-related inflammation. Nature (2008) 34.21
Alternative activation of macrophages. Nat Rev Immunol (2003) 27.53
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol (2004) 19.38
Fibroblasts in cancer. Nat Rev Cancer (2006) 18.95
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20
Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol (2002) 17.85
Marrow stromal cells as stem cells for nonhematopoietic tissues. Science (1997) 17.06
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20
Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 14.55
Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell (2006) 13.79
Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol (2005) 13.03
Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 12.64
Tumor angiogenesis. N Engl J Med (2008) 11.30
Paradoxical roles of the immune system during cancer development. Nat Rev Cancer (2006) 10.57
Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med (2001) 9.99
Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol (2006) 9.82
Distinct role of macrophages in different tumor microenvironments. Cancer Res (2006) 9.29
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 8.79
Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med (1992) 8.46
Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell (2009) 8.21
Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell (2005) 7.90
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 7.61
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis (2009) 7.55
Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol (2001) 7.43
The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer (2008) 7.40
Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med (2008) 7.26
Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell (1998) 7.25
Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood (2008) 7.15
Identification of the haemoglobin scavenger receptor. Nature (2001) 7.05
Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res (2006) 7.02
Immunomodulatory properties of mesenchymal stromal cells. Blood (2007) 6.97
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother (2008) 6.55
Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res (2006) 6.52
Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer (2004) 6.47
Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest (2007) 6.31
Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev (1999) 6.10
Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol (2008) 5.86
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med (2007) 5.65
Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer (2006) 5.60
The role of cyclooxygenases in inflammation, cancer, and development. Oncogene (1999) 5.50
Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res (1996) 5.38
The origin and function of tumor-associated macrophages. Immunol Today (1992) 5.12
Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer (2006) 5.06
The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis (2009) 5.01
Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol (2007) 4.75
Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res (2007) 4.69
Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle (2006) 4.67
Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer (2001) 4.62
APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer (2001) 4.54
Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A (2006) 4.51
The terminology issue for myeloid-derived suppressor cells. Cancer Res (2007) 4.37
Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther (2006) 4.20
The neutrophil as a cellular source of chemokines. Immunol Rev (2000) 4.09
A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood (2005) 3.85
Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev (2007) 3.71
PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell (2009) 3.71
The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia (2008) 3.69
Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res (2007) 3.66
Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J Cell Biol (2006) 3.44
Prostaglandins and cancer. Gut (2005) 3.44
Altered eicosanoid levels in human colon cancer. J Lab Clin Med (1993) 3.32
Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev (2001) 3.27
Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer (2006) 3.05
P68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing Axin from beta-catenin. Cell (2006) 3.04
Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol (2006) 3.00
New vistas on macrophage differentiation and activation. Eur J Immunol (2007) 2.99
The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood (2001) 2.92
Cancer related inflammation: the macrophage connection. Cancer Lett (2008) 2.88
Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res (2004) 2.86
Cancer-associated fibroblasts and tumor growth--bystanders turning into key players. Curr Opin Genet Dev (2009) 2.85
Neutrophil-derived proteins: selling cytokines by the pound. Adv Immunol (1999) 2.77
Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol (2008) 2.76
Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood (2007) 2.74
Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol (2006) 2.67
IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol (2009) 2.64
Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell (2004) 2.60
Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res (2008) 2.56
15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem (2004) 2.55
Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev (2004) 2.52
Platelets and cancer. Lancet Oncol (2002) 2.51
Hyaluronan-cell interactions in cancer and vascular disease. J Biol Chem (2001) 2.45
T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res (2009) 2.43
SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. Nat Genet (2007) 2.39
The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta (2004) 2.30
CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med (2006) 2.30
Structure, development, and molecular pathology of basement membranes. Int Rev Exp Pathol (1986) 2.25
Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. Mol Biol Cell (1998) 2.24
HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. J Biol Chem (2008) 2.22
Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol Biol Cell (2003) 2.11
Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle (2007) 2.10
CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol (2006) 2.10
Natural killer cell receptor signaling. Curr Opin Immunol (2003) 2.10
Eicosanoids and cancer. Nat Rev Cancer (2010) 5.96
Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem (2003) 2.65
Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat Med (2004) 1.89
CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell (2013) 1.71
COX-2 inhibition and colorectal cancer. Semin Oncol (2004) 1.53
Aberrant cannabinoid signaling impairs oviductal transport of embryos. Nat Med (2004) 1.52
Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat Med (2012) 1.47
Requirement of phospholipase D1 activity in H-RasV12-induced transformation. Proc Natl Acad Sci U S A (2005) 1.38
Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2. Oncology (2005) 1.37
Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res (2005) 1.36
Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol (2004) 1.25
APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. J Clin Invest (2011) 1.23
Cyclooxygenase-2-mediated DNA damage. J Biol Chem (2005) 1.18
The role of chemokines in intestinal inflammation and cancer. Curr Opin Pharmacol (2009) 1.16
Cyclooxygenase-1 signaling is required for vascular tube formation during development. Dev Biol (2005) 1.15
Prostaglandins in cancer cell adhesion, migration, and invasion. Int J Cell Biol (2012) 1.09
Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. Clin Cancer Res (2012) 1.08
β-Catenin and p120 mediate PPARδ-dependent proliferation induced by Helicobacter pylori in human and rodent epithelia. Gastroenterology (2011) 1.08
Bmp signaling is required for intestinal growth and morphogenesis. Dev Dyn (2006) 1.07
Cyclopentenone isoprostanes inhibit the inflammatory response in macrophages. J Biol Chem (2005) 1.05
Human enhancer of filamentation 1 Is a mediator of hypoxia-inducible factor-1alpha-mediated migration in colorectal carcinoma cells. Cancer Res (2010) 1.04
Prostaglandin E2 regulates the complement inhibitor CD55/decay-accelerating factor in colorectal cancer. J Biol Chem (2004) 1.02
ANGPTL4 induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer progression. Cancer Res (2011) 1.02
Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer. Cancer Res (2007) 1.00
NUT midline carcinoma: an aggressive intrathoracic neoplasm. J Thorac Oncol (2013) 0.97
Controversy: PPARgamma as a target for treatment of colorectal cancer. Am J Physiol Gastrointest Liver Physiol (2002) 0.97
Stage-specific integration of maternal and embryonic peroxisome proliferator-activated receptor delta signaling is critical to pregnancy success. J Biol Chem (2007) 0.95
Epoxyeicosatrienoic acids: a double-edged sword in cardiovascular diseases and cancer. J Clin Invest (2011) 0.93
The Crosstalk of PTGS2 and EGF Signaling Pathways in Colorectal Cancer. Cancers (Basel) (2011) 0.92
Prostaglandin E2 regulates pancreatic stellate cell activity via the EP4 receptor. Pancreas (2013) 0.91
Associations between obesity and cancer: the role of fatty acid synthase. J Natl Cancer Inst (2012) 0.90
HEF1 is a crucial mediator of the proliferative effects of prostaglandin E(2) on colon cancer cells. Cancer Res (2010) 0.90
Peroxisome proliferator-activated receptors and progression of colorectal cancer. PPAR Res (2008) 0.88
The C-terminal domain LLKIL motif of CXCR2 is required for ligand-mediated polarization of early signals during chemotaxis. J Cell Sci (2004) 0.86
Role of inflammation and inflammatory mediators in colorectal cancer. Trans Am Clin Climatol Assoc (2014) 0.85
Biomarkers, bundled payments, and colorectal cancer care. Genes Cancer (2012) 0.84
Gene expression profiling following constitutive activation of MEK1 and transformation of rat intestinal epithelial cells. Mol Cancer (2006) 0.80
HIG2 promotes colorectal cancer progression via hypoxia-dependent and independent pathways. Cancer Lett (2013) 0.79
The Jeremiah Metzger Lecture: Inflammation, Immune Modulators, and Chronic Disease. Trans Am Clin Climatol Assoc (2015) 0.78
Effects of transforming growth factor-alpha (TGF-alpha) in vitro and in vivo on reovirus replication. DNA Cell Biol (2004) 0.78
PPARγ agonists target aromatase via both PGE2 and BRCA1. Cancer Prev Res (Phila) (2012) 0.76
Ras up-regulation of cyclooxygenase-2. Methods Enzymol (2006) 0.75
Will an aspirin a day keep the endoscope away? Gastroenterology (2003) 0.75
MEK activation suppresses CPT11-induced apoptosis in rat intestinal epithelial cells through a COX-2-dependent mechanism. Dig Dis Sci (2007) 0.75
The physician-scientist in gastroenterology. Gastroenterology (2003) 0.75
The evolution of modern academic medicine continues. Gastroenterology (2002) 0.75
Disease prevention: the future is here. Gastroenterology (2004) 0.75